(2 years, 11 months ago)
Public Bill CommitteesIt is a pleasure to serve under your chairmanship, Mr Dowd. I thank my hon. Friend the Member for Wolverhampton North East for bringing forward this private Member’s Bill, which is, as she said, so important for animal welfare. I join her in thanking my hon. Friend the Member for Truro and Falmouth (Cherilyn Mackrory), who stood in for her when she had to take some time away from this place—although I know she was watching on. It has been an absolute pleasure to work with my hon. Friend the Member for Wolverhampton North East on progressing the Bill. As we have heard today, the measures are sensible. Everybody wants to stop the use of glue traps.
I thank all hon. Members for their contributions, and I thank the organisations that supported the introduction of the Bill; the hon. Member for Rotherham referred to some of them. I reassure her and other Committee members that one of the reasons for a two-year delay was to get this right; we needed those further conversations about how to do this most effectively. My hon. Friend the Member for Wolverhampton North East talked about new technology, such as pressure pads that inform someone electronically when an animal has been caught in a trap, so that it can be dispatched as soon as possible. They are still in use; there is also the point about making sure, through licences, that we know where such devices are. That will have to be done in steps.
As the hon. Member for Newport West said, there is a challenge in that we are slightly out of step with the devolved Administrations. My offer to her before the sitting was to discuss how we can talk to the devolved Ministers with responsibility. On Second Reading, the hon. Member for East Kilbride, Strathaven and Lesmahagow said that she felt that the Scottish Government would be interested in looking at the matter.
On pressure pads or humane traps, such as those where the mouse goes into a tube and can then be released, they are humane only if they are checked; otherwise, the mouse dies probably a far worse death than it would have under other trapping methods. That is why it is important that a licensed person checks the traps regularly, rather than thinking that they have done their job by setting the traps.
That is why we need to think about how we go forward with the licences, applications, resourcing and so on. It is arguably why there is a two-year delay. Once again, campaign groups have run a really good campaign challenging shops not to stock the traps. I take the point about the internet; it is a challenge. I also take the point that several hon. Members made about educating the public and ensuring general awareness. I will answer the inquiry of my hon. Friend the Member for Broadland more directly, but this also goes to his point: setting aside use of the traps by licensed operatives, once we have taken the items away, the likelihood of their being in places where they should not be is diminished.
(3 years, 11 months ago)
Commons ChamberWhen taking a Bill through the House, we always hope that it will be one that hon. Members from both sides can understand, support and improve. Our intention to have a gold standard of medicines and medical device regulation in this country, and to put the patient at the heart of it, has been long understood and has very much formed the foundation stone of the Bill.
I am very grateful for the support of hon. Members here; the spirit of collaboration is how we get this Bill done now—today. I would like to address one or two of the questions that hon. Members brought up. I reiterate my thanks to the hon. Member for Nottingham North (Alex Norris). He was right when he said that the timing of the Cumberlege report was fortuitous. In this House, we have been able to make sure that patient safety has been addressed. He was also right to say that it was a collective effort, and he and other Members were right in saying that the Bill very much reflects the voice of campaigners who often feel that their voices go unheard. Today, they have not gone unheard.
Indeed.
This has been a long time coming, and Members from both this House and the other place have been involved. I pay particular tribute to Janet Peck and Susan Morgan, the constituents of my hon. Friend the Member for Totnes (Anthony Mangnall), and their quiet determination to make sure that their challenges were seen and noticed. The Government then took the right decisions in helping them make sure that this does not happen to others. That was the right thing to do.
The hon. Member for Nottingham North asked me to address two or three points. We plan to respond in full to the report later in 2021. It has been incredibly impactful and has already served to put patient safety at the top of the agenda for the whole health and care system. If it had not been for the covid-19 pandemic, I think we would be discussing little else than patient safety because of the Bill before us. Just as covid-19 impacted on the publication of the report, it has impacted our response time. But I assure the hon. Gentleman that that response will come later in the year.
The hon. Gentleman also asked about the speed of the appointment of a patient safety commissioner. I very much want the right person. I cannot give a precise time, but I want to underscore the importance of patient safety and our belief that the patient safety commissioner will and must be effective in amplifying the voice of patients and improving patient safety in the use of medicines and medical devices. I hope that the process will not take too long, but we must appoint the right person, who will truly give the right voice.
On hub and spoke, which the hon. Gentleman and I both agree is so important, there will be a full public consultation. The Government will then report to Parliament, and include a summary of the concerns raised in the public consultation. To ensure that we get the right model to assist pharmacy going forward, we intend to be totally transparent.
To the hon. Member for Strangford (Jim Shannon), I can give an unequivocal yes. We have a thriving life science sector in the UK, contributing over £80 billion a year to the economy and over a quarter of a million jobs. We want to ensure that the UK remains an important market for medicines and medical devices, and to bring products to market here.
As I close, it is perhaps unusual to be pleased that there have been quite so many changes or challenges on a Bill, but I think they have been the right changes and the right challenges. To that end, I thank all hon. Members who have challenged and who have assisted in those changes. I also thank all those who have assisted behind the scenes—the Bill team, my officials and so on. We have arrived at a Bill that I think carries the support of all sides and of both ends of the Parliament, and one where patients, the sector and the public can understand how we do good work and how this Bill will work for them.
Lords amendment 1 agreed to, with Commons financial privileges waived.
Lords amendments 2 and 3 disagreed to.
Lords amendments 4 to 10 agreed to.
Government amendments (a) to (d) made to Lords amendment 11.
Lords amendment 11, as amended, agreed to.
Lords amendments 12 to 14 disagreed to.
Lords amendments 15 to 21 agreed to.
Government amendments (a) to (c) made to Lords amendment 22.
Lords amendment 22, as amended, agreed to.
Lords amendments 23 to 25 disagreed to.
Lords amendments 26 to 29 agreed to.
Lords amendment 30 disagreed to.
Lords amendment 31 agreed to.
Government amendments (a) to (c) made to Lords amendment 32.
Lords amendment 32, as amended, agreed to.
Lords amendments 33 to 39 agreed to.
Lords amendment 40 disagreed to.
Lords amendments 41 to 47 agreed to.
Lords amendments 48 to 50 disagreed to.
Government amendments (a) to (c) made in lieu of Lords amendments 2, 3, 12 to 14, 23 to 25, 30, 40 and 48 to 50.
Lords amendments 51 to 56 agreed to, with Commons financial privileges waived in respect of Lords amendment 54.